Gene Logic
This article was originally published in The Gray Sheet
Executive Summary
Completes acquisition of Oncormed - giving Oncormed stockholders, including Oncor (23%), 0.4673 shares of Gene Logic common stock for each Oncormed share. The $39.1 mil. deal will issue over 4.8 mil. shares of Gene Logic common stock to Oncormed stockholders. Gene Logic expects to write off a "significant portion" of the purchase price as in-process research and development in the third quarter